Beta Bionics, Inc.

NASDAQ:BBNX

Medical - Equipment & Services

Healthcare
$14.33 +3.18%

+$0.42 today

Market cap
$644.70M
Beta
3.39
P/E (TTM)
-9.1
EPS (TTM)
-$1.50
52W Low $8.80High $32.71

Volume 1.38M

Average 0.99M

BBNX Pre-Tax Margin

Income before tax as a percentage of revenue.

Beta Bionics, Inc.NASDAQ: BBNX

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to -79.3%

Pre-tax margin was -79.3% in Q1 FY2026, up 83.2 pp from a year earlier. On a trailing-twelve-month basis it was -60.3%, up 41.4 pp year over year. Over 3 fiscal years it widened by 36100.7 pp.

Context

  • Pre-tax margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-79.3%-37.3 pp QoQ
Last fiscal yearDec 2025
-73.0%+11.1 pp YoY
LTMMar 2026
-60.3%+41.4 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+83.2 pp——
1 year+11.1 pp——
3 years+36100.7 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-73.0%
Year-over-year change
+11.1pp

Pre-Tax Margin vs competitors

How BBNX compares with its peers on the latest reported figures

  • BBNX's LTM Mar 2026 pre-tax margin of -60.3% is the lowest of the 8 companies compared; the peer median is 16.2%.
  • Its year-over-year change of +41.4 pp is the highest of 6, against a peer median of +4.7 pp.
  • Over three fiscal years its change of +36100.7 pp compares with a peer median of +9.9 pp.
BBNX Competitors Peer median
Pre-Tax Margin for BBNX and competitors
Company Period LTM level YoY 3-year change
ORMPOramed Pharmaceuticals Inc.FY20253766.2% —+5159.6 pp
NVONovo Nordisk A/SLTM Jun 202645.2% +0.0 pp+3.2 pp
DXCMDexCom, Inc.LTM Jun 202625.8% +7.5 pp+9.9 pp
PODDInsulet CorporationLTM Jun 202616.2% +4.7 pp+11.8 pp
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026-6.1% —-2.6 pp
MNKDMannKind CorporationLTM Mar 2026-7.9% -19.1 pp+88.0 pp
TNDMTandem Diabetes Care, Inc.LTM Mar 2026-9.5% +6.3 pp-8.1 pp
BBNXBeta Bionics, Inc.LTM Mar 2026-60.3% +41.4 pp+36100.7 pp
Peer median (excluding BBNX) 16.2%+4.7 pp+9.9 pp

Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue179K12M65.12M100.25M
Cost of Revenue05.69M29.24M44.71M
Gross Profit179K6.31M35.89M55.54M
Gross Margin100.0%52.6%55.1%55.4%
Research & Development31.43M17.94M26.18M34.79M
Selling, General & Admin33.5M24.22M54.96M92.43M
Operating Expenses66.02M42.16M81.14M127.22M
Depreciation & Amortization1.35M1.23M1.15M2.88M
EBITDA(63.4M)(42.87M)(53.61M)(70.32M)
EBITDA Margin-35418.4%-357.4%-82.3%-70.1%
Operating Income(65.84M)(35.85M)(45.25M)(71.68M)
Operating Margin-36784.4%-298.9%-69.5%-71.5%
Interest Income196K1.78M3.91M10.93M
Interest Expense14K000
Other Income / Expenses1.09M(8.25M)(9.51M)(1.52M)
Income Before Tax(64.75M)(44.1M)(54.76M)(73.2M)
Pre-Tax Margin-36173.7%-367.6%-84.1%-73.0%
Income Tax Expense0001K
Net Income(64.75M)(44.1M)(54.76M)(73.2M)
Net Margin-36173.7%-367.6%-84.1%-73.0%
EPS (Basic)(12.96)(8.31)(8.60)(1.81)
EPS (Diluted)(12.96)(8.31)(8.60)(1.81)
Weighted Avg Shares5M5.3M6.37M40.53M
Weighted Avg Shares (Diluted)5M5.3M6.37M40.53M

Beta Bionics, Inc.

NASDAQ:BBNX

Intrinsic Alpha fair value

Locked

Current Price

$14.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.